Preventing cancer recurrence with novel antibody–drug conjugates
Presidential presentations in early breast cancer provide first evidence of ADCs rapidly moving into the curative setting across multiple cancer types
Trastuzumab deruxtecan is moving to the curative setting in early HER2-positive breast cancer
Positive findings from the DESTINY-Breast05 and DESTINY-Breast11 trials suggest that a paradigm change in the treatment of high-risk patients may be imminent
Long-term phase III data reinforce the benefits of CDK4/6 inhibitors in early breast cancer
Follow-up data at 7 and 5 years from monarchE and NATALEE provide reassurance of the sustained benefits of adjuvant CDK4/6 inhibitors in improving survival and reducing relapse
Experts recommend limiting germline genetic testing for breast cancer to seven genes
Newly-released ESMO recommendations critically assess specific germline pathogenic variants in terms of cancer-related mortality and testing implications for patients and their families
The emerging era of liquid biopsy in endocrine-resistant metastatic breast cancer
Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations
First-line use of antibody-drug conjugates: a turning point in metastatic breast cancer
Findings from recently presented studies support an upfront integration of ADCs in the treatment course, but some key questions are pending
AI integration in breast cancer – a long way ahead?
Experts’ discussions during ESMO Breast 2025 provided an overview on promises and challenges in the field
Tucatinib combo continues to show durable benefit in HER2-mutated metastatic breast cancer
Final data from the SGNTUC-019 trial support the use of the agent with trastuzumab in heavily pretreated patients
Promising early results for emiltatug ledadotin in heavily pretreated triple-negative breast cancer
Phase 1 trial data highlights preliminary efficacy and manageable safety of B7-H4–targeted antibody-drug conjugate in women receiving at least one prior topoisomerase-1 ADC
Shaping the future for young women facing breast cancer
Recent studies have refined current knowledge on how to better treat this patient population, taking care of their unique needs and expectations